(-)-Sirpiglenastat
Fibrolamellar Hepatocellular Carcinoma
Explore 26 assets in Fibrolamellar Hepatocellular Carcinoma →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07430202CT.gov A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | — | Not Yet Recruiting | — | — | — |
NCT06027086CT.gov DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Fibrolamellar Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (-)-Sirpiglenastat (this asset) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | CCC · 54 |
| Irinotecan | Children's Oncology Group | P3 | BB |
| Fluorouracilum | M.D. Anderson Cancer Center | P3 | BB |
| Nivolumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | B |
| Sorafenib | St. Jude Children's Research Hospital | P3 | B |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | B |
| Adriamycin | Children's Oncology Group | P3 | B |
| Vincristine Sulfate | Children's Oncology Group | P3 | B |
| Carboplatin | Children's Oncology Group | P3 | B |
+29 more in the Fibrolamellar Hepatocellular Carcinoma cohort
Other indications for (-)-Sirpiglenastat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 52 |
| Cancer | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (-)-Sirpiglenastat in Fibrolamellar Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sirpiglenastat-fibrolamellar-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →